US patent for IML-106 granted
It is a great pleasure to have received the message from the USA, that the in July 2015 filed patent for IML-106 has been approved after long scrutiny by the US patent office this March. The patent extents to the substance IML-106 for the treatment HIV infections and AIDS.
With a patent term adjustment, the period of the patent protection is valid until August 2036. More information and the whole patent text can be requested from us.
Comments are closed.